Roche Moves Cancer Immunotherapy Program Into New Tumor Type
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche’s cancer portfolio drove 2013 sales, and management said it is taking an aggressive approach to developing the “next generation of cancer therapy”: cancer immunotherapy.